Review of the Therapeutic Goods Advertising Framework

In line with the Government's commitment made in 2018 to review the reforms to the therapeutic goods advertising framework within two years from implementation, the review examined the impact of the new advertising measures regarding the commencement of the Therapeutic Goods Amendment (2017 Measures No. 1) Act 2018, with reference to the advertising reforms from the Expert Panel Review of Medicines and Medical Devices Regulation (MMDR Review) and other initiatives announced by the Minister.

The Review was led by Ms Rosemary Sinclair AM, the newly appointed Chief Executive at auDA.

Contents

• 1. Executive summary
• 2. Background, objective, scope and Approach
• 3. Detailed assessments and recommendations
• Attachment A: Stakeholders consulted

Further information

• Australian Government response to the Review of the Reforms to the Therapeutic Goods Advertising Framework
• Independent review of the reforms to the therapeutic goods advertising framework complete